1 – 10 of 19
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies : An up to 10-year follow-up study
- Contribution to journal › Article
- 2021
-
Mark
Predictors of mortality in patients with different apolipoprotein E genotypes—a 20-year follow-up of Alzheimer’s disease.
(2021) 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021)
- Contribution to conference › Abstract
- 2020
-
Mark
Cerebro-spinal fluid biomarker levels : phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease
- Contribution to journal › Article
- 2018
-
Mark
Cerebrospinal fluid biomarker levels: Total tau and phosphorylated tau as markers for rate of progression in Alzheimer’s disease.
(2018) Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting 2018
- Contribution to conference › Abstract
-
Mark
Short-term response to cholinesterase inhibitors in Alzheimer’s disease delays time to nursing home placement
- Contribution to journal › Article
-
Mark
Economic Evaluation of Pharmacological Treatments in Dementia Disorders - A Systematic Literature Review
(2018) In Working Papers
- Working paper/Preprint › Working paper
- 2017
-
Mark
Early- versus late-onset Alzheimer's disease in clinical practice : Cognitive and global outcomes over 3 years
- Contribution to journal › Article
-
Mark
The outcomes of different assessment scales can predict survival in patients with Alzheimer’s disease
(2017) 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2017) In Neurodegenerative Diseases 17(Suppl. 1). p.27-27
- Contribution to journal › Published meeting abstract
-
Mark
Early- versus late-onset Alzheimer disease : Long-term functional outcomes, nursing home placement, and risk factors for rate of progression.
- Contribution to journal › Article
- 2016
-
Mark
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
- Contribution to journal › Article
